Active, Not Recruiting
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients - CA209-743
Updated: 24 March, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Males and Females at least 18 years of age - Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery - ECOG Performance status of 0 or 1 - Available tumor sample for testing - Acceptable blood work Exclusion Criteria: - Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas - Prior chemotherapy for pleural mesothelioma - Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody - History of other malignancy unless the subject has been disease-free for at least 3 years - Active, untreated central nervous system (CNS) metastasis Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
